Table 1.

Patient Clinical and Histopathological Data

Cell line	Age	TNM classification	Grade of the SCC	Prior therapy	Site of the specimen	Survival after initial diagnosis
UM-SCV-1A*	62	T3N2M1	well –poor	none	primary	2 months
UM-SCV-1B*	62	T3N2M1	poor	none	Metastasis	2 months
UM-SCV-2*	86	T3N1M0	poor	surgery	local recurrence	10 months
UM-SCV-3*	66	T2N0M0	mod–well	none	primary	>4, 5 years
UM-SCV-4*	41	T2N2M0	well	none	primary	>4 years
UM-SCV-6*	43	T1N1M0	mod	surgery	primary	15 months
UM-SCV-7*	77	T2N2M0	well –poor	none	primary	1 month
UT-SCV-1*	71	T2N1M0	well	surgery + RTa	Metastasis	1 year
UT-SCV-2*	63	T1N0M0	mod	surgery + RTa + CTb	local recurrence	>13 years
UT-SCV-3*	73	T3N2M0	mod	none	primary	3 months
UT-SCV-4†	31	T2N0M0	mod	none	primary	10 years
UT-SCV-5†	46	T3N2M1	well	none	pleural effusion	5 weeks
UT-SCV-6†	72	T3N2N0	well	none	primary	8 weeks

^aRT indicates radiotherapy.

^bCT indicates chemotherapy.

^*Raitanen M, et. al. Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry. Gynecol Oncol 2004;93(1):155–63.

^†personal communication Dr. Seija Grenman, Turku Central University, Turku, Finland